LY6K and neoplasm: Thus, we wanted to see whether a pharmacological agent that binds with LY6K to induce cell death in vitro could also inhibit tumor cell growth in vivo, and whether this inhibition is accompanied by changes in the tumor microenvironment in the context of immune cell infiltration.